Reports Q1 revenue $15B, consensus $14.72B. “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations. AbbVie’s (ABBV) key growth drivers continue to deliver strong performance and support our enhanced full-year outlook,” said Robert Michael, chairman and chief executive officer, AbbVie. “We are also generating exciting data and advancing numerous programs across all stages of development. Our pipeline progress and solid business fundamentals position AbbVie for robust long-term growth.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves Today, April 29, 2026
- These Are the Stocks Reporting Earnings Today – April 29, 2026
- Notable companies reporting before tomorrow’s open
- AbbVie submits application to FDA for new indication for upadacitinib
- AbbVie submits application to FDA for Skyrizi for subcutaneous induction